Correlation Between NeuroSense Therapeutics and Ignyte Acquisition

Can any of the company-specific risk be diversified away by investing in both NeuroSense Therapeutics and Ignyte Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NeuroSense Therapeutics and Ignyte Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NeuroSense Therapeutics Ltd and Ignyte Acquisition Corp, you can compare the effects of market volatilities on NeuroSense Therapeutics and Ignyte Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NeuroSense Therapeutics with a short position of Ignyte Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of NeuroSense Therapeutics and Ignyte Acquisition.

Diversification Opportunities for NeuroSense Therapeutics and Ignyte Acquisition

0.23

Correlation Coefficient

NeuroSense Therapeutics  Ignyte Acquisition

Modest diversification

The 3 months correlation between NeuroSense and Ignyte is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding NeuroSense Therapeutics Ltd and Ignyte Acquisition Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ignyte Acquisition Corp and NeuroSense Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NeuroSense Therapeutics Ltd are associated (or correlated) with Ignyte Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ignyte Acquisition Corp has no effect on the direction of NeuroSense Therapeutics i.e., NeuroSense Therapeutics and Ignyte Acquisition go up and down completely randomly.

Pair Corralation between NeuroSense Therapeutics and Ignyte Acquisition

Assuming the 90 days horizon NeuroSense Therapeutics Ltd is expected to generate 1.77 times more return on investment than Ignyte Acquisition. However, NeuroSense Therapeutics is 1.77 times more volatile than Ignyte Acquisition Corp. It trades about 0.11 of its potential returns per unit of risk. Ignyte Acquisition Corp is currently generating about -0.18 per unit of risk. If you would invest  21.00  in NeuroSense Therapeutics Ltd on September 16, 2024 and sell it today you would earn a total of  4.00  from holding NeuroSense Therapeutics Ltd or generate 19.05% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	1.44%
Values	Daily Returns

NeuroSense Therapeutics Ltd  vs.  Ignyte Acquisition Corp

NeuroSense Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in NeuroSense Therapeutics Ltd are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NeuroSense Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Ignyte Acquisition Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ignyte Acquisition Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Ignyte Acquisition is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with NeuroSense Therapeutics and Ignyte Acquisition

The main advantage of trading using opposite NeuroSense Therapeutics and Ignyte Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NeuroSense Therapeutics position performs unexpectedly, Ignyte Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ignyte Acquisition will offset losses from the drop in Ignyte Acquisition's long position.

The idea behind NeuroSense Therapeutics Ltd and Ignyte Acquisition Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.